Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06132958 · ClinicalTrials.gov registry record · Phase 3

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

A Phase 3 study of Endometrial Cancer, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 3
Development phase
710
Enrollment target
20
Study locations

NCT06132958: Active Phase 3 study of Endometrial Cancer, sponsored by Merck Sharp & Dohme.

NCT06132958 is a Phase 3 study of Endometrial Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 710 participants, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06132958, a Phase 3 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
710 participants
Enrollment target
20
Study locations

Study Summary

Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.

Primary Outcome

PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first.

Conditions Studied

Endometrial Cancer

Interventions

  • BIOLOGICAL Sacituzumab tirumotecan
  • DRUG Doxorubicin
  • DRUG Paclitaxel
  • DRUG Nab-paclitaxel

Study Locations (20)

Florida

  • Mount Sinai Cancer Center ( Site 4117) - Miami Beach
  • AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 4113) - Orlando
  • Florida Cancer Specialists - East ( Site 7000) - West Palm Beach

Georgia

  • Northside Hospital ( Site 4112) - Atlanta
  • Augusta University ( Site 4116) - Augusta
  • Centricity Research Columbus Cancer Center ( Site 4154) - Columbus

Arizona

  • HonorHealth (HH) ( Site 8000) - Phoenix
  • Arizona Oncology Associates - HOPE ( Site 8002) - Tucson

California

  • UCLA Hematology/Oncology - Westwood (Building 100)-Department of OBGYN, Division of Gynecologic Onc ( Site 4131) - Los Angeles
  • California Pacific Medical Center - Van Ness Campus ( Site 4129) - San Francisco

Louisiana

  • University Medical Center New Orleans ( Site 4133) - New Orleans
  • TRIALS 365 ( Site 4105) - Shreveport

Alabama

  • USA Mitchell Cancer Institute ( Site 4142) - Mobile

Alaska

  • Alaska Womens Cancer Care ( Site 4122) - Anchorage

Connecticut

  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 4114) - New Haven

Trial Details

FieldValue
Enrollment Target 710 participants
Start Date 2023-12-06
Est. Completion 2028-01-10
Phase Phase 3
Merck Sharp & Dohme

558 total trials

What the registry record for NCT06132958 still lists

NCT06132958 is an interventional study that assigns participants to a tested intervention. The registered 710 participants enrollment target is mid-sized for trials with a published cap, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher).

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 4 interventions - of which Sacituzumab tirumotecan is the first listed.

NCT06132958 names 20 study sites across 13 states, led by Florida, Georgia, Arizona.

Frequently Asked Questions

What is clinical trial NCT06132958 about?

NCT06132958 is a clinical study titled "Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)". Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sa...

What is the current status of trial NCT06132958?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2023-12-06. Estimated completion is 2028-01-10.

What conditions does trial NCT06132958 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT06132958?

The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Doxorubicin (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG).

Who is sponsoring clinical trial NCT06132958?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06132958 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06132958's enrollment target sits among peer trials

710 20th of 181 higher than 161 of 181 other Endometrial Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06179160 · 710 participants · Phase 1

    A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

  • NCT06235697 · 710 participants · Phase 3

    Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

  • NCT06470867 · 710 participants · NA

    Randomized Controlled Effectiveness Trial of VA S.A.V.E.

  • NCT06758401 · 714 participants · Phase 3

    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06132958, the US trial registry maintained by the National Library of Medicine. NCT06132958 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.